{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:48:33Z","timestamp":1790790513454,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41366-024-01646-9","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:02:03Z","timestamp":1728691323000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7272-9083","authenticated-orcid":false,"given":"Andr\u00e9 Saad","family":"Cleto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2886-7700","authenticated-orcid":false,"given":"Jo\u00e3o Matheus","family":"Schirlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8359-1657","authenticated-orcid":false,"given":"Mayara","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9307-3108","authenticated-orcid":false,"given":"Victor Hugo Oliveira","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Hellmann","family":"Acras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guinter Sponholz","family":"Neiverth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno Bach","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-5646","authenticated-orcid":false,"given":"Beatriz Moreira Salles","family":"Juliatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janete","family":"Machozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Marinelli","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"1646_CR1","unstructured":"Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. World Obesity. Acessed April 5, 2024. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023."},{"key":"1646_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/nejmoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u20132232. https:\/\/doi.org\/10.1056\/nejmoa2307563.","journal-title":"N Engl J Med"},{"key":"1646_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463\u2013474. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"key":"1646_CR4","unstructured":"Brunton LL, Chabner BA, Knollmann BC. As Bases Farmacolo\u0301gicas Da Terape\u0302utica de Goodman & Gilman. 12th ed. AMGH Editora Ltda; 2012."},{"key":"1646_CR5","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"1646_CR6","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"1646_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/nejmoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl J Med. 2016;375:1834\u20131844. https:\/\/doi.org\/10.1056\/nejmoa1607141.","journal-title":"N. Engl J Med"},{"key":"1646_CR9","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394\u20131407.","journal-title":"N Engl J Med"},{"key":"1646_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s42255-023-00943-3","volume":"6","author":"C Dwibedi","year":"2024","unstructured":"Dwibedi C, Ekstr\u00f6m O, Brandt J, Adiels M, Franz\u00e9n S, Abrahamsson B, et al. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab. 2024;6:50\u201360. https:\/\/doi.org\/10.1038\/s42255-023-00943-3.","journal-title":"Nat Metab"},{"key":"1646_CR11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/nejmoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245\u20132257. https:\/\/doi.org\/10.1056\/nejmoa2208601.","journal-title":"N Engl J Med"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515\u2013527. https:\/\/doi.org\/10.1016\/S2213-8587(19)30192-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1646_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","volume":"26","author":"S Sivalingam","year":"2024","unstructured":"Sivalingam S, Wasehuus VS, Curovic VR, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26:54\u201364. https:\/\/doi.org\/10.1111\/dom.15287.","journal-title":"Diabetes Obes Metab"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724\u20131732. https:\/\/doi.org\/10.2337\/dc19-0749.","journal-title":"Diabetes Care"},{"key":"1646_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/nejmoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl J Med. 2019;381:841\u2013851. https:\/\/doi.org\/10.1056\/nejmoa1901118.","journal-title":"N. Engl J Med"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese Patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8:377\u2013391. https:\/\/doi.org\/10.1016\/S2213-8587(20)30075-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1646_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs. daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA. 2022;327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"1646_CR18","doi-asserted-by":"publisher","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and Efficacy of Oral Semaglutide versus Dulaglutide in Japanese Patients with Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial. 8. Lancet Diabetes Endocrinol. 2020. 8:392-406. https:\/\/doi.org\/10.1016\/S2213-8587(20)30074-7.","DOI":"10.1016\/S2213-8587(20)30074-7"},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50\u2009mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705\u2013719. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6.","journal-title":"Lancet"},{"key":"1646_CR20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA J Am Med Assoc. 2021;325:1414\u20131425. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA J Am Med Assoc"},{"key":"1646_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25\u2009mg and 50\u2009mg compared with 14\u2009mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402:693\u2013704. https:\/\/doi.org\/10.1016\/S0140-6736(23)01127-3.","journal-title":"Lancet"},{"key":"1646_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/nejmoa2032183.","journal-title":"N Engl J Med"},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u20131084. https:\/\/doi.org\/10.1056\/nejmoa2306963.","journal-title":"N Engl J Med"},{"key":"1646_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105\u2013113. https:\/\/doi.org\/10.1016\/S2213-8587(17)30412-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1646_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1646_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"1646_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u2013322. https:\/\/doi.org\/10.1056\/nejmoa1603827.","journal-title":"N Engl J Med"},{"key":"1646_CR28","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","volume":"181","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211\u2013R234. https:\/\/doi.org\/10.1530\/EJE-19-0566.","journal-title":"Eur J Endocrinol"},{"key":"1646_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HCQ Tan","year":"2022","unstructured":"Tan HCQ, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37:65\u201372. https:\/\/doi.org\/10.15605\/jafes.037.02.14.","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"1646_CR30","doi-asserted-by":"publisher","unstructured":"Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.645563.","DOI":"10.3389\/fendo.2021.645563"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01646-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T08:03:07Z","timestamp":1735459387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01646-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1038\/s41366-024-01646-9","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}